Pregled bibliografske jedinice broj: 937363
CARIATIDE study: Evaluation of the impact of educational material on the compliance and persistence rates to adjuvant aromatase inhibitor (AI) medication for postmenopausal women with hormone sensitive early breast cancer
CARIATIDE study: Evaluation of the impact of educational material on the compliance and persistence rates to adjuvant aromatase inhibitor (AI) medication for postmenopausal women with hormone sensitive early breast cancer // Breast, Supplement 1
St. Gallen, Švicarska, 2009. str. 52-52 (poster, međunarodna recenzija, sažetak, stručni)
CROSBI ID: 937363 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
CARIATIDE study: Evaluation of the impact of educational material on
the compliance and persistence rates to adjuvant aromatase inhibitor
(AI) medication for postmenopausal women with hormone sensitive
early breast cancer
Autori
Neven, P ; Serin, D ; Separovic, R ; Ozaslan, C ; Tanner, M
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, stručni
Izvornik
Breast, Supplement 1
/ - , 2009, 52-52
Skup
11 th St. Gallen International Breast Cancer Conference
Mjesto i datum
St. Gallen, Švicarska, 11.03.2009. - 14.03.2009
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
education, compliance, aromatase inhibitor, breast cancer
Sažetak
In the absence of trial data regarding the optimum duration of AI therapy, this study indicates that over one-third (36%)of oncologist surveyed are using adjuvant AIs for more than 5 years. This practice is likely an extrapolation of data from the extended adjuvant setting. The majority of respondents prescribing initial AI therapy are most likely driven by reported data from large RCTs that demonstrated significanty greater benefit for AI therapy over tamoxifen.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
Citiraj ovu publikaciju:
Časopis indeksira:
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE